News
Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...
Stockhead on MSN21h
Dr Boreham’s Crucible: Telix has homework but remains dux of radioimaging class
With multiple clinical trials and approval applications in train, nuclear medicine superstar Telix Pharmaceuticals (ASX:TLX) is like one of those irritatingly brilliant all-round students.
Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback